Any feedback?
Literature summary for 3.4.24.7 extracted from
- Serum matrix metalloprotease-1 and vascular endothelial growth factor - a predict cardiac allograft rejection (2009), Am. J. Transplant., 9, 149-159.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | investigation on the relation of serum matrix metalloprotease MMP-1 and vascular endothelial growth factor VEGF-A concentrations to cardiac allograft rejection. Mean week 1 and week 2 serum MMP-1 concentrations predict rejection. At the optimal cutoff level of >7.5 ng/ml, MMP-1 predicts rejection with 82% sensitivity and 72% specificity. Initial serum MMP-1 <5.3 ng/ml is associated with rejection-free outcome in 80% of patients. Both MMP-1 and VEGF-A predict rejection on the next endomyocardial biopsies, while rejection at endomyocardial biopsy is identified only by VEGF-A. Patients receiving combined cyclosporine-A and everolimus have the lowest serum MMP-1 concentrations. While serum MMP-1 predicts rejection-free outcome and VEGF-A identifies rejection on endomyocardial biopsy, both markers predict rejection in follow-up of cardiac transplant recipients | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
recipients of heart transplantation | - |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
